NASDAQ:VYGR

Voyager Therapeutics (VYGR) Stock Price, News & Analysis

$7.65
+0.08 (+1.06%)
(As of 04/23/2024 ET)
Today's Range
$7.57
$7.78
50-Day Range
$7.15
$10.54
52-Week Range
$6.06
$14.34
Volume
372,354 shs
Average Volume
916,931 shs
Market Capitalization
$415.40 million
P/E Ratio
2.48
Dividend Yield
N/A
Price Target
$19.33

Voyager Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
152.7% Upside
$19.33 Price Target
Short Interest
Bearish
6.13% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.97
Upright™ Environmental Score
News Sentiment
0.15mentions of Voyager Therapeutics in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.64) to ($1.49) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.03 out of 5 stars

Medical Sector

171st out of 909 stocks

Biological Products, Except Diagnostic Industry

17th out of 155 stocks

VYGR stock logo

About Voyager Therapeutics Stock (NASDAQ:VYGR)

Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

VYGR Stock Price History

VYGR Stock News Headlines

top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
NASA's Voyager 1 Phones Home After Months
top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)
AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.
Voyager Therapeutics (NASDAQ:VYGR) Shares Down 1.6%
See More Headlines
Receive VYGR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Voyager Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/23/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:VYGR
Fax
N/A
Employees
162
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$19.33
High Stock Price Target
$30.00
Low Stock Price Target
$14.00
Potential Upside/Downside
+150.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

Net Income
$132.33 million
Pretax Margin
53.49%

Debt

Sales & Book Value

Annual Sales
$250.01 million
Cash Flow
$3.11 per share
Book Value
$5.37 per share

Miscellaneous

Free Float
51,749,000
Market Cap
$418.65 million
Optionable
Optionable
Beta
0.96
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Dr. Alfred W. Sandrock Jr. (Age 66)
    M.D., Ph.D., President, CEO & Director
    Comp: $825.41k
  • Dr. Krystof Bankiewicz M.D.
    Ph.D., Founder
  • Dr. Guangping Gao Ph.D.
    Founder & Member of Scientific Advisory Board
  • Dr. Mark A. Kay M.D. (Age 65)
    Ph.D., Founder
  • Dr. Phillip D. Zamore Ph.D.
    Founder & Member of Scientific Advisory Board
  • Mr. Todd Carter Ph.D. (Age 54)
    Chief Scientific Officer
  • Ms. Jacquelyn Fahey Sandell Esq.
    J.D., Chief Legal Officer
  • Ms. Michelle Quinn Smith
    Chief Human Resources Officer
  • Mr. G. Andre Turenne (Age 50)
    Advisor
    Comp: $600.3k
  • Dr. Maria Lopez-Bresnahan M.B.A.
    M.D., Senior Vice President of Translational Medicine & Clinical Development

VYGR Stock Analysis - Frequently Asked Questions

Should I buy or sell Voyager Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Voyager Therapeutics in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" VYGR shares.
View VYGR analyst ratings
or view top-rated stocks.

What is Voyager Therapeutics' stock price target for 2024?

7 brokerages have issued twelve-month target prices for Voyager Therapeutics' shares. Their VYGR share price targets range from $14.00 to $30.00. On average, they expect the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 152.7% from the stock's current price.
View analysts price targets for VYGR
or view top-rated stocks among Wall Street analysts.

How have VYGR shares performed in 2024?

Voyager Therapeutics' stock was trading at $8.44 at the start of the year. Since then, VYGR stock has decreased by 9.4% and is now trading at $7.65.
View the best growth stocks for 2024 here
.

Are investors shorting Voyager Therapeutics?

Voyager Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 3,330,000 shares, an increase of 44.2% from the March 15th total of 2,310,000 shares. Based on an average trading volume of 750,600 shares, the short-interest ratio is presently 4.4 days.
View Voyager Therapeutics' Short Interest
.

When is Voyager Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our VYGR earnings forecast
.

How were Voyager Therapeutics' earnings last quarter?

Voyager Therapeutics, Inc. (NASDAQ:VYGR) issued its quarterly earnings results on Wednesday, February, 28th. The company reported $1.25 earnings per share for the quarter, topping the consensus estimate of ($0.59) by $1.84. The business earned $90.06 million during the quarter, compared to the consensus estimate of $4.95 million. Voyager Therapeutics had a trailing twelve-month return on equity of 63.89% and a net margin of 52.93%.

What ETFs hold Voyager Therapeutics' stock?

ETFs with the largest weight of Voyager Therapeutics (NASDAQ:VYGR) stock in their portfolio include Franklin Genomic Advancements ETF (HELX) and iShares Neuroscience and Healthcare ETF (IBRN).Invesco Nasdaq Future Gen 200 ETF (QQQS).

What other stocks do shareholders of Voyager Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Voyager Therapeutics investors own include Micron Technology (MU), REGENXBIO (RGNX), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Amarin (AMRN), CRISPR Therapeutics (CRSP), Inovio Pharmaceuticals (INO), Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT).

Who are Voyager Therapeutics' major shareholders?

Voyager Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Allspring Global Investments Holdings LLC (0.18%) and Hunter Perkins Capital Management LLC (0.12%). Insiders that own company stock include Alfred Sandrock, Ecor1 Capital, Llc, Glenn Pierce, Julie Burek, Neurocrine Biosciences Inc, Omar Khwaja, Peter P Pfreundschuh, Robert W Hesslein, Robin Swartz, Rock Ventures Iii LP Third and Todd Alfred Carter.
View institutional ownership trends
.

How do I buy shares of Voyager Therapeutics?

Shares of VYGR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:VYGR) was last updated on 4/23/2024 by MarketBeat.com Staff

From Our Partners